Paxlovid costs about $1,390 for a single five-day course at its commercial list price, nearly triple what the U.S. government previously paid per course ($530) when it purchased the drug directly from Pfizer. The shift from government-funded free distribution to commercial sales in late 2023 is the most immediate reason patients now face a bill, but the price itself reflects a combination of manufacturing complexity, patent exclusivity, and Pfizer’s positioning in a market where the alternative is a hospital stay that costs far more.
The Shift From Free to Commercial
For the first two years of Paxlovid’s availability, the federal government bought millions of courses from Pfizer and distributed them at no charge to patients. That arrangement ended when the government’s stockpile ran out and Pfizer moved to commercial sales starting in late 2023. As part of the transition agreement with the Department of Health and Human Services, Pfizer set a list price of $1,390 per course, more than double the roughly $530 per course the government had negotiated.
That list price is what Pfizer charges before rebates and discounts to insurers and pharmacy benefit managers. What you actually pay depends entirely on your insurance. Someone with robust commercial insurance might see a modest copay. Someone without prescription drug coverage could face the full price.
Manufacturing Is Genuinely Complex
Part of the price reflects real production costs. The active ingredient in Paxlovid, nirmatrelvir, is a chemically complex molecule that requires an unusually demanding manufacturing process. Pfizer’s commercial synthesis uses over 70 unique raw materials spread across multiple supply nodes around the world. Each of the three key starting materials required five to seven global suppliers during the emergency rollout, compared to the two suppliers a typical new drug would need.
The synthesis itself involves multiple specialized chemical steps, starting from building blocks derived from amino acids and requiring carefully controlled reactions at each stage. This isn’t a simple pill to stamp out. The supply chain complexity and sheer number of reagents and solvents needed at multiple vendor sites drive production costs well above those of a standard small-molecule drug.
Patent Protection Blocks Generic Competition
The biggest structural reason Paxlovid stays expensive is that Pfizer holds patents that could extend protection through 2041, based on application filing dates. Without generic competition in the U.S., there is no downward price pressure from rival manufacturers. Generic versions do exist in a handful of countries: Bangladesh, for instance, has two manufacturers producing the drug under emergency use authorizations for their local market. But those generics are not available in the United States or most high-income countries.
Until patents expire or are successfully challenged, Pfizer remains the sole supplier in major markets and can price accordingly.
The Hospitalization Math
Pfizer and its supporters often frame the $1,390 price against the cost of a COVID-19 hospitalization, which can run tens of thousands of dollars. The logic is straightforward: if the drug keeps even a small percentage of high-risk patients out of the hospital, it pays for itself many times over.
The reality is more nuanced. Cost-effectiveness analyses have found that at commercial prices, Paxlovid is most clearly cost-effective for the highest-risk patients, particularly unvaccinated people over 80. For younger, vaccinated adults whose hospitalization risk is already low, the math is much less favorable. A study published in Frontiers in Public Health found that for vaccinated adults aged 40 to 59, the drug would need to cost almost nothing to be considered cost-effective by standard thresholds. This doesn’t mean the drug doesn’t work for those patients. It means the price is hard to justify on a population level when most of those patients would recover without it.
What You Might Actually Pay
Your out-of-pocket cost depends heavily on your coverage. Most commercial insurance plans cover Paxlovid, though copays vary. Medicare Part D plans generally cover it as well, but some beneficiaries face high cost-sharing that can make the drug unaffordable in practice.
For people who can’t afford their share, Pfizer and the federal government operate assistance programs. As of March 2025, Medicare patients who are underinsured or lack prescription drug coverage may qualify for the U.S. Government Patient Assistance Program, which provides Paxlovid at no cost. The same program extends to eligible Medicaid, Tricare, and Veterans Affairs patients who face high copays. Uninsured and underinsured individuals can access Paxlovid through a separate Pfizer-run federal assistance program that runs through 2028.
If you’re prescribed Paxlovid and the pharmacy quotes a price that seems unmanageable, asking about these programs before walking away is worth the extra few minutes. Eligibility screening typically happens at the pharmacy or through a dedicated enrollment process.